Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
Status:
Completed
Trial end date:
2018-03-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of zilucoplan (RA101495) in
patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients
in the study: the first group will include patients who have never received eculizumab for
treatment of PNH. The second group will include patients who have received treatment with
eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495
for 12 weeks.